Recombinant Human IL-15 Protein, Active, Low Endotoxin

Beta LifeScience SKU/CAT #: BEP-0014
Recombinant Human IL-15 (2 ug/lane) on SDS-PAGE under reducing (R) conditions. The gel was stained using Coomassie® Blue showing a single band at 13 kDa and purity greater than 95%.
Recombinant Human IL-15 (2 ug/lane) on SDS-PAGE under reducing (R) conditions. The gel was stained using Coomassie® Blue showing a single band at 13 kDa and purity greater than 95%.

Recombinant Human IL-15 Protein, Active, Low Endotoxin

Beta LifeScience SKU/CAT #: BEP-0014
/
Size

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Product Name Recombinant Human IL-15 Protein
Target Symbol IL15
Alternative Names Interleukin 15, IL15, MGC9721
Accession Number P40933
Expression System E.Coli.
Molecular Weight 12.9 kDa (predicted, monomer)
Sequence Asn49-Ser162, with an N-terminal Met
Purity >95% by SDS-PAGE and quantitative densitometry by Coomassie® Blue staining.
Activity Determined by a cell proliferation assay using mouse CTLL-2 cells. The ED50 for this effect is typically <0.5 ng/mL.
Formulation Lyophilized from sterile PBS with Trehalose, pH 7.4
Endotoxin Level <0.05 EU/1ug of the protein as determined by the LAL method.
Shipping Shipped at ambient temperature.
Stability & Storage 12 months from date of receipt at -20°C to -70°C, lyophilized powder. 3 months at -20°C to -70°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw cycles.
Reconstitution Reconstitute at 100 ug/mL in sterile PBS.
Target Function IL-15 is a cytokine closely related to IL-2 in that it stimulates CD4+ Th cells, CD8+ Tc cells and NK cells. Notably, IL-15 is not associated with a strong Treg response and uses a variation in receptor signaling to distinguish its mechanism from IL-2. IL-15 predominately uses a cell-to-cell juxtacrine interaction involving an IL-15 responsive cell expressing the IL-2 R beta (CD122)/common gamma chain (CD132) complex and, in a process termed transpresentation, IL-15 bound to IL-15 R alpha (CD215) on the surface of second, effector cell completes the signaling interaction. In a less regulated fashion, free IL-15 is able to induce signaling through the IL-2 R beta (CD122)/common gamma chain (CD132) complex. Through these interactions IL-15 is also associated with an exercise-induced skeletal response and interstitial adipose metabolism. IL-15 is being investigated for its potential to improve the efficacy of adoptive cell therapies (ACT), such as CAR-T cell therapy and TCR-engineered T cell therapy. IL-15 is being investigated in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1 antibodies) and other cytokines (e.g., IL-2), to enhance anti-tumor immune responses.
Tissue Specificity IL-15 expression has been reported in bone marrow stromal cells, muscle tissue, epithelial cells, and adipose tissue
Cellular Localization Cell surface and secreted protein forms
Involvement In Disease Dysregulation of IL-15 has been implicated in inflammatory disorders like allergic asthma, chronic obstructive pulmonary disease (COPD) and psoriasis; autoimmune disorders such as rheumatoid arthritis and multiple sclerosis; metabolic disorders such as obesity, insulin resistance; cancer tumor metastasis and immune evasion.

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

More from All Products
Tn5 Transposase
  • Expression system: E.coli;
CAT#: TN5-BL01
Sale
SDS-PAGE analysis of Human USP9X (Ubiquitin Carboxyl-Terminal Hydrolase 9X) - Recombinant Protein, CAT# BLT-07739P, showing >90% purity under 15% SDS-PAGE (Reduced)
Human USP9X (Ubiquitin Carboxyl-Terminal Hydrolase 9X) - Recombinant Protein
  • Molecule: USP9X;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-GST;
  • Sequence: 1554-1995aa;
CAT#: BLT-07739P

Save $139
Sale
SDS-PAGE analysis of Human TRIM21 (E3 Ubiquitin-Protein Ligase Trim21) - Recombinant Protein, CAT# BLT-07371P, showing >90% purity under 15% SDS-PAGE (Reduced)
Human TRIM21 (E3 Ubiquitin-Protein Ligase Trim21) - Recombinant Protein
  • Molecule: TRIM21;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-6His;
  • Sequence: 268-465aa;
CAT#: BLT-07371P

Save $139
Sale
SDS-PAGE analysis of Human RECK (Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs) - Recombinant Protein, CAT# BLT-08901P showing >90% purity under 15% SDS-PAGE (Reduced)
Human RECK (Reversion-Inducing Cysteine-Rich Protein With Kazal Motifs) - Recombinant Protein
  • Molecule: RECK;
  • Species: Human;
  • Expression system: Mammalian Cell;
  • Tag: C-6His;
  • Sequence: 27-941;
CAT#: BLT-08901P

Save $139
Sale
SDS-PAGE analysis of Human SHFL (Shiftless Antiviral Inhibitor Of Ribosomal Frameshifting Protein) - Recombinant Protein, CAT# BLT-08873P showing >85% purity under 15% SDS-PAGE (Reduced)
Human SHFL (Shiftless Antiviral Inhibitor Of Ribosomal Frameshifting Protein) - Recombinant Protein
  • Molecule: SHFL;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-6His+sumo;
  • Sequence: 1-291;
CAT#: BLT-08873P

Save $139
Sale
SDS-PAGE analysis of Human SFTPA1 (Pulmonary Surfactant-Associated Protein A1) - Recombinant Protein, CAT# BLT-08790P showing >90% purity under 15% SDS-PAGE (Reduced)
Human SFTPA1 (Pulmonary Surfactant-Associated Protein A1) - Recombinant Protein
  • Molecule: SFTPA1;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-6His;
  • Sequence: 21-248;
CAT#: BLT-08790P

Save $139
Recently viewed